GeoVax Labs (NASDAQ:GOVX) vs. MeiraGTx (NASDAQ:MGTX) Head-To-Head Survey

MeiraGTx (NASDAQ:MGTX) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Profitability

This table compares MeiraGTx and GeoVax Labs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
GeoVax Labs	N/A	-743.64%	-394.74%

Volatility & Risk

MeiraGTx has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.66, indicating that its share price is 266% more volatile than the S&P 500.

Insider & Institutional Ownership

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by insiders. Comparatively, 0.2% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares MeiraGTx and GeoVax Labs”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$397.50 million	2.84	-$114.20 million	$0.71	16.55
GeoVax Labs	$2.49 million	1.12	-$21.47 million	($11.34)	-0.03

GeoVax Labs has lower revenue, but higher earnings than MeiraGTx. GeoVax Labs is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for MeiraGTx and GeoVax Labs, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	0	2	5	1	2.88
GeoVax Labs	1	1	1	0	2.00

MeiraGTx currently has a consensus price target of $26.17, indicating a potential upside of 122.70%. GeoVax Labs has a consensus price target of $150.00, indicating a potential upside of 39,582.54%. Given GeoVax Labs’ higher probable upside, analysts clearly believe GeoVax Labs is more favorable than MeiraGTx.

Summary

MeiraGTx beats GeoVax Labs on 12 of the 15 factors compared between the two stocks.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

About GeoVax Labs

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.